Publications by authors named "Falk Ehmann"

Claim this Profile
A
A Fast Path from Innovation to Safe and Effective Medicines.
Peter Arlett, Falk Ehmann, Ralf Herold, Evdokia Korakianiti, Pierpaolo Moscariello

Clin Pharmacol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action.
Jasmine Gratton, Peter Arlett, Falk Ehmann, Daniel Prieto-Alhambra, Patrice Verpillat

Nat Rev Drug Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New approach methodologies: EU regulatory horizons.
Mariana Edwards, Oriane Blanquie, Orla Moriarty, Sonja Beken, Falk Ehmann

Nat Rev Drug Discov· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into new approach methodology innovation: an EMA perspective.
Mariana Edwards, Oriane Blanquie, Falk Ehmann

Nat Rev Drug Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EU regulatory horizons for Alzheimer's disease.
Oriane Blanquie, Lorenzo Guizzaro, Ralf Herold, Marion Haberkamp, André Elferink, Falk Ehmann

Lancet Neurol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into Early Interactions on Innovative Developments with European Regulators.
David W Uster, Valentina Cordo', Emmanuel Cormier, Falk Ehmann

Ther Innov Regul Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying and overcoming challenges in the EMA's qualification of novel methodologies: a two-year review.
Ana Drmić, Riccardo Saccà, Thorsten Vetter, Falk Ehmann

Front Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Innovation Network as a hub for medicines innovation in Europe.
Eleonora Agricola, Caroline Auriche-Benichou, Helena Baiao, Oriane Blanquie, Teodora Bodea, Falk Ehmann

Nat Rev Drug Discov· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report of the European Medicines Agency Conference on RNA-Based Medicines.
Falk Ehmann, Andreas Kuhn, Anna Maria Gerdina Pasmooij, Anthony Humphreys, Arjon Van Hengel

Nucleic Acid Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enabling technologies driving drug research and development.
Panna Vass, Dara Sevkan Akdag, Gabriel Enemark Broholm, Jesper Kjaer, Anthony J Humphreys, Falk Ehmann

Front Med (Lausanne)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020.
Elisabeth Bakker, Natalie M Hendrikse, Falk Ehmann, Daniëlla S van der Meer, Jordi Llinares Garcia

Clin Pharmacol Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and Beyond.
Natalie M Hendrikse, Jordi Llinares Garcia, Thorsten Vetter, Anthony J Humphreys, Falk Ehmann

Front Med (Lausanne)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency.
Laura Patricia Orellana García, Falk Ehmann, Philip A Hines, Armin Ritzhaupt, Angela Brand

Front Med (Lausanne)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary on ICH guideline on genomic sampling and data management-enabling opportunities in drug development and patient treatment.
Falk Ehmann, Jeroen Aerssens, Rebecca Blanchard

Br J Clin Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementing the EU in vitro diagnostic regulation - a European regulatory perspective on companion diagnostics.
Armin Ritzhaupt, Ivana Hayes, Falk Ehmann

Expert Rev Mol Diagn· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanomedicines in the EU-Regulatory Overview.
Ruben Pita, Falk Ehmann, Marisa Papaluca

AAPS J· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.
Marisa Papaluca, Martina Greco, Enrico Tognana, Falk Ehmann, Agnès Saint-Raymond

Expert Rev Clin Pharmacol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union.
Falk Ehmann, Marisa Papaluca, Francesca Di Giuseppe, Luca Pani, Andrea Eskova

Expert Opin Pharmacother· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Medicines Agency initiatives and perspectives on pharmacogenomics.
Falk Ehmann, Laura Caneva, Marisa Papaluca

Br J Clin Pharmacol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Francesco Pignatti, Falk Ehmann, Robert Hemmings, Bertil Jonsson, Micha Nuebling

Clin Cancer Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling the risk-benefit impact of H1N1 influenza vaccines.
Lawrence D Phillips, Barbara Fasolo, Nikolaos Zafiropoulous, Hans-Georg Eichler, Falk Ehmann

Eur J Public Health· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
Falk Ehmann, Kumiko Sakai-Kato, Ruth Duncan, Dolores Hernán Pérez de la Ossa, Ruben Pita

Nanomedicine (Lond)· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.
Marc Maliepaard, Charity Nofziger, Marisa Papaluca, Issam Zineh, Yoshiaki Uyama, Falk Ehmann

Nat Rev Drug Discov· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars: what clinicians should know.
Martina Weise, Marie-Christine Bielsky, Karen De Smet, Falk Ehmann, Niklas Ekman

Blood· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Setting the stage for biosimilar monoclonal antibodies.
Christian K Schneider, Camille Vleminckx, Iordanis Gravanis, Falk Ehmann, Jean-Hugues Trouvin

Nat Biotechnol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis